31st Annual J.P. Morgan Healthcare Conference
Who's 'Afrezza' the FDA? Not MannKind, Still Plugging Away
By Randy Osborne
Friday, January 11, 2013
As FDA-mandated Phase III trials near their finish with MannKind Corp.'s beleaguered inhaled insulin product Afrezza, Alfred Mann, CEO and major funder of the company, took to the lectern at the J.P. Morgan Healthcare Conference to deliver a familiar message: It works, the device is simple and patients will use it.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.